Search Results

The Dutch Association for Innovative Medicines (VIG) releases a detailed report highlighting the sector\'s €8.5 billion gross added value, warning that cost-containment measures threaten patient access, clinical trials, and Europe\'s biopharma sovereignty.

The latest EFPIA Patients W.A.I.T. Indicator report reveals that Irish patients wait an average of 801 days to access newly approved medicines, prompting calls for an overhaul of the HSE and NCPE reimbursement processes and a dedicated mechanism for rare disease orphan drugs.

The UK government and the pharmaceutical industry have launched a series of pilot schemes designed to accelerate NHS patient access to innovative medicines — a direct consequence of the US-UK pharmaceutical trade arrangement that has already rewritten the terms of how Britain prices, approves, and funds new drugs. But with a BMJ analysis warning of £45 billion in diverted NHS resources and up to 229,000 excess deaths by 2036, the pilots are arriving in the middle of one of the most contested healthcare policy disputes in a generation.

A definitive 5,000-word guide to public relations for pharmaceutical, biotech, and MedTech professionals. Learn how to build a PR strategy from scratch, which tools to use, how to write for journalists and LinkedIn, and the exact frameworks used by the world's leading life science communications teams.

A practitioner-level guide to building genuine professional authority on LinkedIn as a pharmaceutical, biotech, or MedTech professional. Covers profile architecture, content strategy, engagement tactics, thought leadership frameworks, and the exact playbooks used by the most followed life science voices on the platform.

An in-depth analysis of the warnings from pharmaceutical lobby chief Stefan Oelrich regarding European cost-cutting reforms, global pricing shifts, and the threat to clinical research and manufacturing.

A step-by-step compliance-safe LinkedIn guide exclusively for Medical Science Liaisons. Covers profile optimisation, what to post, what never to post, KOL engagement, off-label rules, digital medical affairs strategy, and how to build scientific credibility on LinkedIn without breaching pharmaceutical regulatory guidelines.

A complete step-by-step guide for pharmaceutical, biotech and life science professionals on building a credible, visible personal brand on LinkedIn - without ever crossing compliance lines or risking proprietary data exposure. Covers brand strategy, content pillars, storytelling frameworks, and the exact boundaries every pharma professional must respect.

The European Commission has proposed the European Biotech Act to turbocharge the EU's health biotechnology sector, streamline regulations, and regain global competitiveness against the US and China.